Nasal Corticosteroids Market to Reach Over $11.4 Billion by 2034 Amid Rising Chronic Respiratory Disorders | Transparency Market Research, Inc.
02 déc. 2024 06h32 HE
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc.-, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The global nasal corticosteroids market (marché des corticostéroïdes nasaux), valued at US$ 6.6 billion in...
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
10 sept. 2020 18h00 HE
|
Lyra Therapeutics
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
03 sept. 2020 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
05 août 2020 16h05 HE
|
Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
04 août 2020 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs
04 août 2020 08h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference
30 juil. 2020 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update
24 juil. 2020 08h30 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development
07 juil. 2020 08h30 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index
25 juin 2020 08h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...